Related Experiment Video
Updated: Mar 22, 2026
Lipidomics and Transcriptomics in Neurological Diseases
Published on: March 18, 2022
High-Throughput LC-MS/MS Proteomic Analysis of a Mouse Model of Mesiotemporal Lobe Epilepsy Predicts Microglial
Vasiliki Bitsika1, Venceslas Duveau2, Julia Simon-Areces3
1Biotechnology Division, Biomedical Research Foundation, Academy of Athens , Soranou Efessiou 4, 11527 Athens, Greece.
Abstract:
Uncovering the molecular mechanisms of mesiotemporal lobe epilepsy (MTLE) is critical to identify therapeutic targets. In this study, we performed global protein expression analysis of a kainic acid (KA) MTLE mouse model at various time-points (1, 3, and 30 days post-KA injection -dpi), representing specific stages of the syndrome. High-resolution liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS), in combination with label-free protein quantification using three processing approaches for quantification, was applied. Following comparison of KA versus NaCl-injected mice, 22, 53, and 175 proteins were differentially (statistically significant) expressed at 1, 3 and 30dpi, respectively, according to all three quantification approaches. Selected findings were confirmed by multiple reaction monitoring LC-MS/MS. As a positive control, the astrocyte marker GFAP was found to be upregulated (3dpi: 1.9 fold; 30dpi: 12.5 fold), also verified by IHC. The results collectively suggest that impairment in synaptic transmission occurs even right after initial status epilepticus (1dpi), with neurodegeneration becoming more extensive during epileptogenesis (3dpi) and sustained at the chronic phase (30dpi), where also extensive glial- and astrocyte-mediated inflammation is evident. This molecular profile is in line with observed phenotypic changes in human MTLE, providing the basis for future studies on new molecular targets for the disease.
Insights
This study reveals key molecular changes in a mouse model of mesiotemporal lobe epilepsy (MTLE). Protein analysis shows synaptic dysfunction, neurodegeneration, and inflammation, offering insights into epilepsy progression and potential therapeutic targets.
Area of Science:
- Neuroscience
- Molecular Biology
- Biochemistry
Background:
- Mesiotemporal lobe epilepsy (MTLE) is a common epilepsy syndrome.
- Understanding the molecular underpinnings of MTLE is crucial for developing effective therapies.
- Current therapeutic strategies for MTLE often have limitations, necessitating the identification of novel targets.
Purpose of the Study:
- To investigate the global protein expression changes in a kainic acid-induced mouse model of MTLE.
- To identify molecular alterations at different stages of the epilepsy syndrome: acute (1 day post-injection), epileptogenesis (3 days post-injection), and chronic (30 days post-injection).
- To provide a molecular basis for understanding MTLE pathogenesis and discovering new therapeutic targets.
Main Methods:
- Global protein expression analysis using high-resolution liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS).
- Label-free protein quantification employing three distinct processing approaches.
- Validation of selected protein expression changes using multiple reaction monitoring LC-MS/MS and immunohistochemistry (IHC).
Main Results:
- A significant number of differentially expressed proteins were identified at 1, 3, and 30 days post-kainic acid injection (22, 53, and 175 proteins, respectively).
- Early impairment in synaptic transmission was observed at 1 day post-injection.
- Progressive neurodegeneration and sustained glial- and astrocyte-mediated inflammation were evident at later time points (3 and 30 days post-injection), with GFAP upregulation confirmed.
- The identified molecular profile aligns with the phenotypic progression of MTLE.
Conclusions:
- The study elucidates the dynamic molecular changes occurring throughout the development of MTLE.
- Early synaptic transmission deficits and later neuroinflammation are key molecular events in MTLE.
- The findings provide a foundation for future research into novel molecular targets for MTLE treatment.
